Bridging of Amicrobial resistance Surveillance systems In Community Settings across Europe
Surveillance
- Olivier Lemenand, Nantes University Hospital, France (Coordinator)
- Constantinos Tsioutis, European University Cyprus, Cyprus (Observer)
- Carlos Palos, Hospital Beatriz Ângelo, Portugal (Observer)
- Jesus Oteo Iglesias, Instituto de Salud Carlos III, Spain (Observer)
- Georgios Chamilos, University of Crete, Greece (Observer)
- Nico T. Mutters, University Hospital Bonn, Germany (Observer)
- Elena Carrara, University of Verona, Italy (Observer)
- Andreas Kronenberg, University of Bern, Switzerland (Observer)
- Belén Aracil García, Instituto de Salud Carlos III, Spain (Observer)
- María Pérez-Vázquez, Instituto de Salud Carlos III, Spain (Observer)
- Anne Gaelle Leroy, Nantes University Hospital, France (Observer)
- Gabriel Birgand, Nantes University Hospital, France (Observer)
- Petra Apfalter, Ordensklinikum Linz GmbH Elisabethinen, Austria (Observer)
- Anne Berger-Carbonne, Sante Publique France, France (Observer)
- Spyros Pournaras, National and Kapodistrian University of Athens, Greece (Observer)
- Luke Moore, Imperial College London, United Kingdom (Observer)
- Timothy Rawson, Imperial College London, United Kingdom (Observer)
- Hilary Humphreys, Royal College of Surgeons in Ireland, Ireland (Observer)
In 2019, 1.27 million deaths were directly attributable to antimicrobial resistance (AMR) globally. This makes AMR one of the leading cause of death worldwide. Among its determinant are the overuse and the misuse of antibiotics. For this reason, AMR surveillance is necessary to monitor its progression, improve our understanding of its diffusion and support local efforts to promote appropriate use of antibiotics. Actually in Europe, AMR surveillance is mainly focused on invasive isolates reported for inpatients by hospitals or national agencies (EARS-net). The importance of AMR in primary care is scarcely documented in EU and its burden remains unclear today. The aim of the proposed Network “BASICS” would be to map existing initiatives and identify needs for AMR Surveillance in Community Settings in Europe. It will rely on experts in AMR surveillance from several countries in Europe that will participate to physical and online workshops during 2 years in order to map the clinical labs structuring and the existing surveillance networks across Europe and to define the priority indicators needed to monitor AMR surveillance in the community. It is expected that it will help to promote the convergence of national data of AMR surveillance in the community toward an existing or a future European online platform. Once data of AMR available, it would allow a Europe-wide benchmarking and could guide the elaboration of recommendations for appropriate use of antibiotics and serve as a tool for research on the understanding of AMR.
